JP7017509B2 - がんを治療するための四環式キノロン類似体の併用療法 - Google Patents

がんを治療するための四環式キノロン類似体の併用療法 Download PDF

Info

Publication number
JP7017509B2
JP7017509B2 JP2018526088A JP2018526088A JP7017509B2 JP 7017509 B2 JP7017509 B2 JP 7017509B2 JP 2018526088 A JP2018526088 A JP 2018526088A JP 2018526088 A JP2018526088 A JP 2018526088A JP 7017509 B2 JP7017509 B2 JP 7017509B2
Authority
JP
Japan
Prior art keywords
cancer
compound
optionally substituted
alkyl
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018526088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534321A5 (enExample
JP2018534321A (ja
Inventor
ジョン ソーン，
Original Assignee
センワ バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センワ バイオサイエンシズ インコーポレイテッド filed Critical センワ バイオサイエンシズ インコーポレイテッド
Publication of JP2018534321A publication Critical patent/JP2018534321A/ja
Publication of JP2018534321A5 publication Critical patent/JP2018534321A5/ja
Priority to JP2021197736A priority Critical patent/JP2022020003A/ja
Application granted granted Critical
Publication of JP7017509B2 publication Critical patent/JP7017509B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Endocrinology (AREA)
JP2018526088A 2015-11-20 2016-11-09 がんを治療するための四環式キノロン類似体の併用療法 Active JP7017509B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021197736A JP2022020003A (ja) 2015-11-20 2021-12-06 がんを治療するための四環式キノロン類似体の併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258211P 2015-11-20 2015-11-20
US62/258,211 2015-11-20
PCT/US2016/061176 WO2017087235A1 (en) 2015-11-20 2016-11-09 Combination therapy of tetracyclic quinolone analogs for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021197736A Division JP2022020003A (ja) 2015-11-20 2021-12-06 がんを治療するための四環式キノロン類似体の併用療法

Publications (3)

Publication Number Publication Date
JP2018534321A JP2018534321A (ja) 2018-11-22
JP2018534321A5 JP2018534321A5 (enExample) 2020-02-13
JP7017509B2 true JP7017509B2 (ja) 2022-02-08

Family

ID=58717690

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018526088A Active JP7017509B2 (ja) 2015-11-20 2016-11-09 がんを治療するための四環式キノロン類似体の併用療法
JP2021197736A Withdrawn JP2022020003A (ja) 2015-11-20 2021-12-06 がんを治療するための四環式キノロン類似体の併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021197736A Withdrawn JP2022020003A (ja) 2015-11-20 2021-12-06 がんを治療するための四環式キノロン類似体の併用療法

Country Status (11)

Country Link
US (4) US10857156B2 (enExample)
EP (1) EP3377068B1 (enExample)
JP (2) JP7017509B2 (enExample)
KR (2) KR20180113976A (enExample)
CN (2) CN108601789A (enExample)
AU (3) AU2016355268B2 (enExample)
CA (1) CA3005730A1 (enExample)
IL (1) IL259423A (enExample)
RU (1) RU2752506C2 (enExample)
TW (1) TWI730013B (enExample)
WO (1) WO2017087235A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
JP7017509B2 (ja) 2015-11-20 2022-02-08 センワ バイオサイエンシズ インコーポレイテッド がんを治療するための四環式キノロン類似体の併用療法
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CA3037928A1 (en) * 2016-09-23 2018-03-29 The Johns Hopkins University Combinatory treatment strategies of cancer based on rna polymerase i inhibition
EP3601286A4 (en) 2017-03-28 2020-09-23 Pimera, Inc. NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR
WO2018200571A1 (en) 2017-04-25 2018-11-01 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1h-indene analogs and methods using same
CN111918667A (zh) * 2018-02-05 2020-11-10 特沙诺有限公司 儿科尼拉帕尼配制剂和儿科治疗方法
CN112334133A (zh) * 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法
CN111867598A (zh) * 2018-03-13 2020-10-30 国立大学法人大阪大学 肿瘤免疫赋活剂
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
GB201816825D0 (en) * 2018-10-16 2018-11-28 Phoremost Ltd Target for anti-cancer therapy
US20230158071A1 (en) * 2018-12-07 2023-05-25 Crage Medical Co., Limited Tumor combined immunotherapy
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
CN110075061A (zh) * 2019-03-13 2019-08-02 安庆瑄宇医药科技有限公司 一种尼拉帕尼口服液及其制备方法
EP4013421A4 (en) 2019-08-14 2023-08-23 Senhwa Biosciences, Inc. TETRACYCLIC COMPOUNDS AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
KR20220124739A (ko) * 2020-01-09 2022-09-14 아스트라제네카 아베 암의 치료를 위한 병용 요법
CN113491768A (zh) * 2020-04-01 2021-10-12 深圳市罗湖区人民医院 Cd137抗体在制备促进nk细胞表达cd16分子的药物中的应用
TW202227082A (zh) * 2020-08-12 2022-07-16 美商施維雅製藥有限公司 用於治療癌症之組合療法
CN114409681A (zh) * 2022-03-18 2022-04-29 信义核新(北京)生物科技有限公司 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用
CN115160341B (zh) * 2022-07-18 2023-07-18 中国医学科学院医学实验动物研究所 苯并噁嗪类化合物及其药物用途
AU2023334696A1 (en) * 2022-08-30 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN116063328B (zh) * 2023-03-29 2023-06-20 信义核新(北京)生物科技有限公司 一种四环喹诺酮化合物、药学上可接受的盐及其应用
WO2024222630A1 (zh) * 2023-04-23 2024-10-31 信义核新(北京)生物科技有限公司 喹诺酮衍生物及其在抗肿瘤中的应用
WO2024242545A1 (ko) * 2023-05-23 2024-11-28 (주) 메티메디제약 칼슘 락테이트를 활성 성분으로 포함하는 암 백신 조성물 및 그 용도
WO2025101688A1 (en) * 2023-11-08 2025-05-15 Mary Hitchcock Memorial Hospital For Itself And On Behalf Of Dartmouth-Hitchcock Clinic (Collectively Doing Business As Dartmouth-Hitchcock) Combination therapy using tetrathiomolybdate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519827A (ja) 2003-03-12 2006-08-31 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
JP2007537291A (ja) 2004-05-13 2007-12-20 イコス・コーポレイション ヒトホスファチジルイノシトール３−キナーゼデルタの阻害剤としてのキナゾリノン
JP2010540663A (ja) 2007-10-05 2010-12-24 サイリーン ファーマシューティカルズ インコーポレーティッド キノロン類似体およびそれに関連する方法
JP2015518826A (ja) 2012-05-15 2015-07-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔ Ｐｄ−１／ｐｄ−ｌ１シグナル伝達を破壊することによる癌免疫療法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1165508B1 (en) 1999-04-07 2004-06-23 The University of Virginia Patent Foundation Anticancer calcium channel blockers
JP2005511743A (ja) 2001-12-13 2005-04-28 ウォックハート・リミテッド 新世代の三重標的化したキラルな広域スペクトラム抗菌性の７位置換ピペリジノ−キノロンカルボン酸誘導体、その調製方法、組成物、および医薬としての使用
US6900224B2 (en) 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
WO2005033108A1 (en) 2003-09-22 2005-04-14 Janssen Pharmaceutica, N.V. 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
PL2305221T3 (pl) 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
WO2006034113A2 (en) 2004-09-17 2006-03-30 Cylene Pharmaceuticals, Inc. Quinolone analogs as cell proliferation inhibitors
US7816524B2 (en) 2005-08-05 2010-10-19 Cylene Pharmaceuticals, Inc. Methods of preparing quinolone analogs
JP2009504192A (ja) 2005-08-19 2009-02-05 サイリーン ファーマシューティカルズ インコーポレーティッド ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用
AR057555A1 (es) 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
US20090291437A1 (en) 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
EP2023720A4 (en) 2006-05-17 2009-06-10 Cylene Pharmaceuticals Inc TETRACYCLIC IMIDAZOLE ANALOG
WO2007146831A2 (en) 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
WO2007146813A2 (en) 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Pyridinone analogs as cell proliferation inhibitors
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
US20110065687A1 (en) 2007-04-17 2011-03-17 Michael Schwaebe Hydrazide compounds and uses thereof
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
AR071774A1 (es) 2008-05-14 2010-07-14 Takeda Pharmaceutical Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso.
US9359605B2 (en) * 2011-03-11 2016-06-07 Sarissa Inc. Method of treating cancer by inhibition of DNA repair proteins
US20140086839A1 (en) 2011-03-17 2014-03-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
US9556271B2 (en) * 2011-12-01 2017-01-31 The Brigham And Women's Hospital, Inc. Anti-CEACAM1 recombinant antibodies for cancer therapy
WO2013133876A1 (en) * 2011-12-07 2013-09-12 The Regents Of The University Of California Biomarkers for prediction of response to parp inhibition in breast cancer
US9044421B2 (en) * 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
ES2754207T3 (es) 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos
KR102410090B1 (ko) 2014-02-21 2022-06-16 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제
JP7017509B2 (ja) 2015-11-20 2022-02-08 センワ バイオサイエンシズ インコーポレイテッド がんを治療するための四環式キノロン類似体の併用療法
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
CN112334133A (zh) 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法
EP4013421A4 (en) 2019-08-14 2023-08-23 Senhwa Biosciences, Inc. TETRACYCLIC COMPOUNDS AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
CA3151116A1 (en) 2019-08-14 2021-02-18 Hshiou-Ting Liu Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519827A (ja) 2003-03-12 2006-08-31 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
JP2007537291A (ja) 2004-05-13 2007-12-20 イコス・コーポレイション ヒトホスファチジルイノシトール３−キナーゼデルタの阻害剤としてのキナゾリノン
JP2010540663A (ja) 2007-10-05 2010-12-24 サイリーン ファーマシューティカルズ インコーポレーティッド キノロン類似体およびそれに関連する方法
JP2015518826A (ja) 2012-05-15 2015-07-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔ Ｐｄ−１／ｐｄ−ｌ１シグナル伝達を破壊することによる癌免疫療法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER DISCOVERY，2015年10月21日，(2016)vol. 6，pp.59-70
Oncotarget，2015年06月05日，Vol. 6, No. 20，pp. 18094-18104
Oncotarget，2015年10月12日，Vol. 6, No. 33，pp. 34846-34858

Also Published As

Publication number Publication date
CN119185322A (zh) 2024-12-27
RU2752506C2 (ru) 2021-07-28
US20210113584A1 (en) 2021-04-22
US10857156B2 (en) 2020-12-08
AU2021225157B2 (en) 2023-10-05
US20220088029A1 (en) 2022-03-24
AU2023229524B2 (en) 2025-10-02
JP2018534321A (ja) 2018-11-22
AU2016355268B2 (en) 2021-08-19
RU2021121695A (ru) 2021-09-23
EP3377068A1 (en) 2018-09-26
IL259423A (en) 2018-07-31
CN108601789A (zh) 2018-09-28
JP2022020003A (ja) 2022-01-27
US20190224209A1 (en) 2019-07-25
WO2017087235A1 (en) 2017-05-26
US11229654B2 (en) 2022-01-25
AU2021225157A1 (en) 2021-09-30
US20170143737A1 (en) 2017-05-25
CA3005730A1 (en) 2017-05-26
RU2018122172A (ru) 2019-12-20
KR20180113976A (ko) 2018-10-17
EP3377068C0 (en) 2025-03-26
TW201720833A (zh) 2017-06-16
KR20250065935A (ko) 2025-05-13
TWI730013B (zh) 2021-06-11
AU2023229524A1 (en) 2023-09-28
AU2016355268A1 (en) 2018-06-14
EP3377068B1 (en) 2025-03-26
EP3377068A4 (en) 2019-06-19
RU2018122172A3 (enExample) 2020-02-12

Similar Documents

Publication Publication Date Title
JP7017509B2 (ja) がんを治療するための四環式キノロン類似体の併用療法
TWI887465B (zh) 用於伊卡洛斯(ikaros)或愛露斯(aiolos)介導之病症之有利療法
JP2023182577A (ja) 化学療法計画中の免疫応答の保護
TWI746449B (zh) 使用阿吡莫德治療癌症之方法
CN110913861B (zh) G1t38的形态学形式及其制造方法
CN106659716A (zh) 阿吡莫德组合物及其使用方法
TW201639578A (zh) 阿吡莫德之活性代謝物及其用途
CN113365610A (zh) 制备和递送比生群制剂的方法
US20240391912A1 (en) Morphic forms of cft7455 and methods of manufacture thereof
JP2025540907A (ja) Ｒｅｔ－ｌｄｄタンパク質分解誘導剤
RU2786570C2 (ru) Комбинированная терапия тетрациклическими аналогами хинолона для лечения рака
HK1261603A1 (en) Combination therapy of tetracyclic quinolone analogs for treating cancer
HK1261603B (en) Combination therapy of tetracyclic quinolone analogs for treating cancer
CN118660884A (zh) Cft7455的晶型物及其制造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200911

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211206

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211206

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211214

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220127

R150 Certificate of patent or registration of utility model

Ref document number: 7017509

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250